These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1605715)

  • 21. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
    Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
    Gust R; Karl J; Faderl M; Schönenberger H
    Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
    Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
    J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
    Hartmann RW; Heindl A; Schneider MR; Schönenberger H
    J Med Chem; 1986 Mar; 29(3):322-8. PubMed ID: 3005573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
    Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
    J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
    Karl J; Schönenberger H
    Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity.
    Gust R; Bernhardt G; Spruss T; Krauser R; Koch M; Schönenberger H; Bauer KH; Schertl S; Lu Z
    Arch Pharm (Weinheim); 1995 Sep; 328(9):645-53. PubMed ID: 7487421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carrier mediated action of platinum complexes on estrogen receptor positive tumors.
    Knebel N; Schiller CD; Schneider MR; Schönenberger H; von Angerer E
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):293-9. PubMed ID: 2702983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity.
    Schneider MR; Schiller CD; Humm A; Spruss T; Schönenberger H; Amselgruber W; Sinowatz F
    Prostate; 1989; 15(2):135-48. PubMed ID: 2798231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity.
    Lee K; Tashiro T; Noji M
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic ester derivatives of the mammary tumor inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.
    Schwarz W; Hartmann RW; Engel J; Schneider MR; Schönenberger H
    Arch Pharm (Weinheim); 1990 Feb; 323(2):121-4. PubMed ID: 2159273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(ii) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(ii) complexes in relation to the complex structure.
    Konovalov B; Živković MD; Milovanović JZ; Djordjević DB; Arsenijević AN; Vasić IR; Janjić GV; Franich A; Manojlović D; Skrivanj S; Milovanović MZ; Djuran MI; Rajković S
    Dalton Trans; 2018 Oct; 47(42):15091-15102. PubMed ID: 30303498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Dec; 333(12):404-14. PubMed ID: 11199470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
    vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of selectively acting platinum complexes.
    Schönenberger H; Wappes B; Jennerwein M; Berger M
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():125-30. PubMed ID: 6733714
    [No Abstract]   [Full Text] [Related]  

  • 38. Anticancer drugs: estrophilic cisplatin derivatives.
    Engel J; Schönenberger H; Lux F; Hilgard P
    Cancer Treat Rev; 1987 Dec; 14(3-4):275-83. PubMed ID: 2830970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
    Hartmann RW; Buchborn H; Kranzfelder G; Schönenberger H; Bogden A
    J Med Chem; 1981 Oct; 24(10):1192-7. PubMed ID: 6276542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, characterization and cytotoxicity evaluation of some new platinum(II) complexes of tetrazolo[1,5-a]quinolines.
    Bekhit AA; El-Sayed OA; Al-Allaf TA; Aboul-Enein HY; Kunhi M; Pulicat SM; Al-Hussain K; Al-Khodairy F; Arif J
    Eur J Med Chem; 2004 Jun; 39(6):499-505. PubMed ID: 15183908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.